Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies

Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second-line treatment for those who are resistant or intolerant to therapy with imatinib. Dasatinib is superior to imatinib in terms o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Fang, Xu, Qiling, Li, Qiang, Cui, Zheng, Li, Weiming, Zeng, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939513/
https://www.ncbi.nlm.nih.gov/pubmed/36814818
http://dx.doi.org/10.3389/fonc.2023.1113462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939513/
https://www.ncbi.nlm.nih.gov/pubmed/36814818
http://dx.doi.org/10.3389/fonc.2023.1113462

Ejemplares similares